MedTrace Logo

Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial

NCT01152060 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2010-06-29

No results posted yet for this study

Summary

Lamivudine treatment for HBV-DNA negative HBV-GN patients.

Conditions

  • Proteinuria
  • HBVe-antigen

Sponsors & Collaborators

  • Nanchang University

    lead OTHER

Principal Investigators

  • Gaosi XU, MD & PhD · second affiliated hospital to nanchang university

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-11-30
Completion
2010-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01152060 on ClinicalTrials.gov